** Shares of Emyria EMD.AX rise 2.9% to A$0.036, their highest levels since Dec 11
** The early-stage drug developer announces positive interim analysis results of its MDMA-assisted therapy programme for Post Traumatic Stress Disorder (PTSD)
** Co says therapy programme clinically reduces PTSD symptoms in first eight patients
** Stock rose as much as 14.3% to A$0.040 earlier in the day, marking its biggest intraday gain since Jan 22
** About 1.3 mln shares change hands, 6.9 times the 30-day average of 189,038
** Stock has risen 5.9% YTD, including current session's moves
(Reporting by Manasi Dasa Sundeep in Bengaluru)
((Manasi.DasaSundeep@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.